학술논문
PF-06804103, a site-specific Anti-HER2 antibody–drug conjugate for the treatment of HER2-expressing breast, gastric, and lung cancers
Document Type
Article
Author
Graziani, E.I.; Puthenveetil, S.; Nathan Tumey, L.; Bikker, J.; Casavant, J.; O'Donnell, C.J.; Sung, M.; Ma, D.; Narayanan, B.; Charati, M.B.; Golas, J.; Hosselet, C.; Lucas, J.; Rosfjord, E.; Loganzo, F.; Gerber, H.-P.; Sapra, P.; Marquette, K.; Bennett, E.M.; Tchistiakova, L.; Rohde, C.M.; Hu, G.; Guffroy, M.; Falahatpisheh, H.; Finkelstein, M.; Clark, T.; Barletta, F.
Source
In: Molecular Cancer Therapeutics . (Molecular Cancer Therapeutics, 1 October 2020, 19(10):2068-2078)
Subject
Language
English
ISSN
15388514
15357163
15357163